

Registry for long-term follow-up of CML patients who discontinued Imatinib after Complete Cytogenetic Response

2nd Form (Discontinuation of Imatinib)

(to be filled out at time of 1st discontinuation of Imatinib and every 3 months thereafter)

Demographics/Patient Characteristics		
Center		<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Patient ID		<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Date of birth	ddmmmyy	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Gender	0=male 1=female	<input type="checkbox"/>
Disease characteristics		
WHO Performance Scale	%	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Karnofsky-Index	%	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Disease related symptoms	0=no 1=yes	<input type="checkbox"/>
Extramedullary manifestations (apart from liver and spleen)	0=no 1=yes	<input type="checkbox"/>
	If yes, please specify	_____
Spleen size	cm below costal margin, palpated	<input type="checkbox"/> <input type="checkbox"/>
	The longest diameter in ultrasound, cm	<input type="checkbox"/> <input type="checkbox"/>
Hematology		
Hemoglobin	g/dl	<input type="checkbox"/> <input type="checkbox"/> . <input type="checkbox"/>
Hematokrit	%	<input type="checkbox"/> <input type="checkbox"/>
WBC	x 10 ⁹ /l	<input type="checkbox"/> <input type="checkbox"/> . <input type="checkbox"/>
Platelets	x 10 ⁹ /l	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Differential (PB)		
(a minimum of 200 cells should be counted under the microscope)		
Blasts	%	<input type="checkbox"/> <input type="checkbox"/>
Promyelocytes	%	<input type="checkbox"/> <input type="checkbox"/>
Myelocytes	%	<input type="checkbox"/> <input type="checkbox"/>
Metamyelocytes	%	<input type="checkbox"/> <input type="checkbox"/>
Bands	%	<input type="checkbox"/> <input type="checkbox"/>
Polymorphic nucleated cells	%	<input type="checkbox"/> <input type="checkbox"/>
Basophils	%	<input type="checkbox"/> <input type="checkbox"/>
Eosinophils	%	<input type="checkbox"/> <input type="checkbox"/>
Monocytes	%	<input type="checkbox"/> <input type="checkbox"/>
Lymphocytes	%	<input type="checkbox"/> <input type="checkbox"/>
Normoblasts	(pro 100 leukocytes)	<input type="checkbox"/> <input type="checkbox"/>
Differential (BM)		
BM cellularity (histopathology or smear)	1=low 2=normal 3=high	<input type="checkbox"/>
Blasts in BM	% na=no aspiration nd=not done	<input type="checkbox"/> <input type="checkbox"/>
Promyelocytes in BM	% na=no aspiration nd=not done	<input type="checkbox"/> <input type="checkbox"/>
Basophils in BM	% na=no aspiration nd=not done	<input type="checkbox"/> <input type="checkbox"/>
Eosinophils in BM	% na=no aspiration nd=not done	<input type="checkbox"/> <input type="checkbox"/>

Center | | | | | Patient ID | | | | |
 Date of birth (ddmmyy) | | | | | | | | |
 Gender (0=male, 1=female) | |

Cytogenetic features		
Ph-chromosome status	1=positive 2=negative 3=unknown	
Number of evaluated metaphases		
Number of Ph-positive metaphases		
Karyotype		_____
Other clonal chromosomal anomalies in Ph-positive cells, if yes, please specify % and type	0=no	
	1=yes	
	%	
Other clonal chromosomal anomalies in Ph-negative cells, if yes, please specify % and type	0=no	
	1=yes	
	%	
Molecular biology		
Date of molecular analysis	ddmmyy	
Source of material	1=PB 2=BM	
Volume	ml	
Ratio BCR-ABL/ABL	%	.
Other control gene	Please specify	_____
Ratio BCR-ABL/other gene	%	.
Nested PCR	1=positive 2=negative 4=not done	
Date of molecular analysis	ddmmyy	
Source of material	1=PB 2=BM	
Volume	ml	
Ratio BCR-ABL/ABL	%	.
Other control gene	Please specify	_____
Ratio BCR-ABL/other gene	%	.
Nested PCR	1=positive 2=negative 4=not done	
Date of molecular analysis	ddmmyy	
Source of material	1=PB 2=BM	
Volume	ml	
Ratio BCR-ABL/ABL	%	.
Other control gene	Please specify	_____
Ratio BCR-ABL/other gene	%	.
Nested PCR	1=positive 2=negative 4=not done	
Level of BCR-ABL transcript, i.e. quantitative	1=positive 2=negative 3=unknown	
Treatment		
End of Imatinib treatment	ddmmyy	
	please specify the cause	_____

Institution: _____ Date (ddmmyy): | | | | | | | | Signature: _____

Center | | | | | Patient ID | | | | |
 Date of birth (ddmmyy) | | | | | | | | | |
 Gender (0=male, 1=female) | |

New CML treatment (after discontinuation of Imatinib treatment)	New CML treatment: 0=no 1=yes <input type="checkbox"/>
	If yes, please specify below:
	Drug: _____
	Dosis: _____
	Period of administration (ddmmyy): from to
	Drug: _____
	Dosis: _____
Period of administration: from to	
Drug: _____	
Dosis: _____	
Period of administration: from to	
Drug: _____	
Dosis: _____	
Period of administration: from to	
More than one episode of Imatinib discontinuation	0=no 1=yes <input type="checkbox"/>
If yes, please document accordingly	
Transplantation	
Transplantation	0=no 1=yes <input type="checkbox"/>
	If yes, please specify the date (ddmmyy)
Stage of disease at transplantation	1=first chronic phase 2=second or higher chronic phase 3=accelerated phase 4=blast phase <input type="checkbox"/>
Survival status	
Blast crisis	0=no 1=yes <input type="checkbox"/>
	If yes, please specify the date (ddmmyy)
Date of death	ddmmyy
Cause of death	1=CML-related 2=BMT-related 3=treatment associated toxicity 4=not CML-related <input type="checkbox"/>
	If not CML-related, please specify